Skip to main content
. 2023;24(9):3169–3182. doi: 10.31557/APJCP.2023.24.9.3169

Table 4.

Effect of Different Variables on Overall Survival (OS) of AML Patients

Total No. No. of Events Cumulative survival
at 2year (%)
Median survival time (months) P value
Whole group 111 83 0.198 2.07 -
Gender
Female 52 44 0.056 1.55 0.014
Male 59 39 0.313 3.45
Age (years)
≤40 57 41 0.183 4.14 0.216
>40 54 42 0.2 1.41
TLC (n=109)
≤100 X109/L 79 60 0.185 2.96 0.487
>100 X109/L 30 23 0.214 1.41
Hemoglobin (n=109)
≤10 g/dl 104 80 0.176 2 0.34
>10 g/dl 5 3 0.400 12.2
Platelets (n=109)
≤100 X 109/L 87 66 0.185 2 0.745
>100 X 109/L 22 17 0.205 3.42
PB blasts%
≤ 50 31 23 0.148 3.55 0.71
> 50 80 60 0.221 2
BMA blast %
≤ 50 18 12 0.216 8.72 0.347
> 50 93 71 0.202 2
BMA cellularity
Hypercellular 95 70 0.204 2.07 0.92
Hypocellular 7 6 10.76
Normocellular 9 7 0.222 1.35
Lymphadenopathy (n=105)
No 62 44 0.245 2.07 0.618
Yes 43 34 0.142 2.34
Organomegally (n=105)
No 68 48 0.226 3.55 0.167
Yes 37 30 0.17 2
FAB classification (n=105)
M1&M2 54 40 0.219 1.55 0.441
M4&M5 51 37 0.219 3.68
CD34 (n=110)
No 53 38 0.24 2.43 0.674
Yes 57 44 0.162 2.07
DR (n=110)
No 29 23 0.162 2 0.656
Yes 81 59 0.228 2.43
CD7 (n=110)
No 91 69 0.204 2.07 0.387
Yes 19 13 0.167 4.14
NPM (n=100)
Mutant 14 5 0.595 0.005
Wild 86 70 0.133 1.61
Total No. No. of Events Cumulative survival
at 2year (%)
Median survival time (months) P value
FLT3 ITD
Mutant 38 32 0.118 1.55 0.035
Wild 73 51 0.242 3.42
Combined FLT3&NPM with ITD ratio (n=100)
Favourable (a) 11 3 0.682 NA 0.002
Unfavorable (b) 13 12 NA 1.32
Intermediate (b) 76 60 0.153 1.74
ITD Ratio (n=27)
≤ 0.525 13 9 0.308 6.71 0.114
>0.525 14 12 NR 1.32
TKD (n=110)
Mutant 5 3 0.3 7.89 0.489
Wild 105 79 0.194 2.07
DNMTA (n=110)
Mutant 11 8 0.227 2.96 0.755
Wild 99 74 0.198 2
IDH1&IDH2
Either IDH1 and or IDH2 mutant 10 8 0.2 0.82 0.37
Both wild 101 75 0.197 2.43
TET2
Mutant 58 43 0.189 2.83 0.645
Wild 53 40 0.207 1.55
CR (n=98)
No 47 46 0.021 0.79 <0.001
Yes 51 24 0.413 14.44